YMAB Y-mAbs Therapeutics Inc
Price (delayed)
$4.54
Market cap
$205.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.67
Enterprise value
$138.88M
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product
Highlights
The company's debt fell by 42% YoY and by 24% QoQ
YMAB's revenue is up by 3.7% since the previous quarter and by 3.4% year-on-year
The quick ratio has contracted by 27% YoY but it has grown by 5% from the previous quarter
The net income has contracted by 38% YoY and by 24% from the previous quarter
The EPS has contracted by 37% YoY and by 24% from the previous quarter
Key stats
What are the main financial stats of YMAB
Market
Valuations
Earnings
Shares outstanding
45.22M
Market cap
$205.29M
Enterprise value
$138.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.21
Price to sales (P/S)
2.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.58
Revenue
$87.69M
Gross profit
$72.43M
Operating income
-$31.2M
Net income
-$29.67M
EBIT
-$31.2M
EBITDA
-$30.67M
Free cash flow
-$15.71M
Per share
Balance sheet
Liquidity
EPS
-$0.67
EPS diluted
-$0.67
Free cash flow per share
-$0.35
Book value per share
$2.05
Revenue per share
$1.98
TBVPS
$2.65
Total assets
$119.9M
Total liabilities
$27.9M
Debt
$820,000
Equity
$92M
Working capital
$74.81M
Debt to equity
0.01
Current ratio
4.16
Quick ratio
3.67
Net debt/EBITDA
2.17
Margins
Efficiency
Dividend
EBITDA margin
-35%
Gross margin
82.6%
Net margin
-33.8%
Operating margin
-35.6%
Return on assets
-23.4%
Return on equity
-31.3%
Return on invested capital
-120.1%
Return on capital employed
-32.4%
Return on sales
-35.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
YMAB stock price
How has the Y-mAbs Therapeutics stock price performed over time
Intraday
-2.58%
1 week
-5.61%
1 month
-8.47%
1 year
-68.82%
YTD
-42.02%
QTD
2.48%
Financial performance
How have Y-mAbs Therapeutics's revenue and profit performed over time
Revenue
$87.69M
Gross profit
$72.43M
Operating income
-$31.2M
Net income
-$29.67M
Gross margin
82.6%
Net margin
-33.8%
The net income has contracted by 38% YoY and by 24% from the previous quarter
The company's net margin fell by 34% YoY and by 20% QoQ
YMAB's operating income is down by 22% year-on-year and by 10% since the previous quarter
The operating margin has contracted by 17% YoY and by 6% from the previous quarter
Growth
What is Y-mAbs Therapeutics's growth rate over time
Valuation
What is Y-mAbs Therapeutics stock price valuation
P/E
N/A
P/B
2.21
P/S
2.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.58
The EPS has contracted by 37% YoY and by 24% from the previous quarter
YMAB's P/B is 63% below its 5-year quarterly average of 6.0 and 61% below its last 4 quarters average of 5.7
Y-mAbs Therapeutics's equity has decreased by 9% YoY
The stock's price to sales (P/S) is 88% less than its 5-year quarterly average of 18.6 and 64% less than its last 4 quarters average of 6.4
YMAB's revenue is up by 3.7% since the previous quarter and by 3.4% year-on-year
Efficiency
How efficient is Y-mAbs Therapeutics business performance
Y-mAbs Therapeutics's return on equity has shrunk by 51% YoY and by 27% QoQ
Y-mAbs Therapeutics's ROA has decreased by 44% YoY and by 26% from the previous quarter
The ROS has contracted by 17% YoY and by 6% from the previous quarter
The company's return on invested capital fell by 10% QoQ but it rose by 2.4% YoY
Dividends
What is YMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for YMAB.
Financial health
How did Y-mAbs Therapeutics financials performed over time
The quick ratio has contracted by 27% YoY but it has grown by 5% from the previous quarter
The current ratio has contracted by 25% YoY but it has grown by 6% from the previous quarter
The company's debt is 99% lower than its equity
The company's debt fell by 42% YoY and by 24% QoQ
Y-mAbs Therapeutics's equity has decreased by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.